Heterozygous familial hypercholesterolemia was associated with increased type 2 diabetes risk, especially among those with obesity and statin use.

FSH levels were independently associated with an increased risk for hip fracture among older men and women regardless of bone density.

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Sotagliflozin is an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor. The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and ...